Deep Research
EClinCloud research grounded in public raw data, regulatory documents, and peer-reviewed evidence.
CTIS Trial Results Disclosure 2026: Summary Results, Layperson Summaries and Clinical Study Reports — What Sponsors Must Prepare and WhenA sponsor workpaper for CTIS results disclosure: map the applicable clock, separate secure submission from public publication, and control each artifact.
RTSM Trial Supply Planning 2026: How to Turn Registry Flags into a Protocol-Level Supply DecisionA protocol-level framework for deciding when randomized drug trials need RTSM, using registry flags as triage—not as a substitute for supply-chain facts.
Clinical Trial Protocol Complexity 2026: Endpoints, Multicenter Countries and Study-Build Workload on ClinicalTrials.govPublic protocol files store outcome, group, country and facility multipliers, not EDC hours. Median studies are small; Phase 3 industry interventional trials sit on a different build surface.
FDA PFDD Guidance 3 and ClinicalTrials.gov 2026: PRO vs ClinRO Tokens, Patient-Reported Outcome Registration, and eCOA ImplementationFDA PFDD Guidance 3 is a fit-for-purpose selection file. ClinicalTrials.gov outcome text almost never stores COA type; PRO language is common and still not validation.
FDA Warning Letters, BIMO Computerized Systems and 21 CFR 312.62 Records in 2026: What Clinical Trial Data Integrity, Part 11 and eTMF Inspections Actually CiteFDA warning letters and BIMO observations cite investigator records and protocol compliance far more than EDC or eTMF products. Part 11 is not the dominant public inspection object.
CTIS vs ClinicalTrials.gov vs China CTR: What a Failed WHO ICTRP Join Means in 2026ClinicalTrials.gov, CTIS, China Drug Trials and WHO ICTRP use different identity contracts. A failed NCT-CT number-CTR join is usually the key, not proof the study is unregistered.